In this line of evidence, given the availability of small molecules to specifically activate jmjC-containing histone demethylases54–56, our study sheds light in the identification of Phf2 as potential “druggable” epigenetic target to prevent NAFLD progression. Here, PHF2 is linked to metabolic dysfunction-associated steatotic liver disease.